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Evidence accumulated over more than
50 years of epidemiologic and clinical
research has established the adverse effects of
air pollution on human health. The London
smog of December 1952 caused > 4,000
excess deaths (Ministry of Health 1954); in
spite of the dramatic decreases in levels of air
pollution that have been achieved since then,
the association between air pollution and
cardiorespiratory morbidity and mortality
persists (Anderson et al. 1996; Dockery et al.
1993; Pope et al. 2002). These associations
are strongest for fine particulate matter (PM
< 2.5 µm in aerodynamic diameter; PM2.5),
and the majority of excess deaths are due to
cardiovascular events (Pope 2000). Despite
the strength of the epidemiologic evidence
and the emergence of promising hypotheses,
the constituents and biological mechanisms
responsible for the cardiovascular effects of air
pollution are only beginning to emerge.
Exposure to particulate air pollution has
been associated with exercise-induced myo-
cardial ischemia in patients with coronary
heart disease (Pekkanen et al. 2002) and with
triggering acute myocardial infarction (Peters
et al. 2001a). These findings are limited by
exposure misclassification, the effect of poten-
tial confounding environmental and social
factors, and the lack of mechanistic data
(Stone 2004). Controlled exposures of air pol-
lutants can help address these shortcomings by
providing a precisely defined exposure in a
regulated environment that facilitates investi-
gation with validated biomarkers and surro-
gate measures of cardiovascular health. Using
a carefully characterized exposure system, we
previously showed that exposure to dilute
diesel exhaust causes lung inflammation (Salvi
et al. 1999), depletion of airway antioxidant
defenses (Behndig et al. 2006), and impair-
ment of vascular and fibrinolytic function
(Mills et al. 2005). Moreover, we recently
described ischemic and thrombotic effects in
patients with coronary heart disease (Mills
et al. 2007). Although controlled exposure to
diesel exhaust is an excellent model for study-
ing the effects of pure combustion-derived air
pollution, we acknowledge that ambient air
pollution contains a range of particulate pollu-
tants from a variety of atmospheric sources. In
the last few years, technology has been devel-
oped that can deliver a continuous flow of air
in which the concentration of ambient partic-
ulate is increased 10- to 60-fold in real-time
(Kim et al. 2001; Sioutas et al. 1995, 1997).
The principle advantage of these concentra-
tors is that they provide real-world inhalation
exposures under controlled conditions.
In previous studies, exposure to fine
(0.15–2.5 µm in aerodynamic diameter) con-
centrated ambient particles (CAPs) induced
mild pulmonary inflammation in healthy
adults (Ghio et al. 2000) and altered heart rate
variability in the elderly (Devlin et al. 2003)
and in asthmatic and healthy younger adults
(Gong et al. 2003). Furthermore, exposure to
fine CAPs plus ozone causes peripheral arterial
vasoconstriction (Brook et al. 2002) and
increases in arterial pressure (Urch et al.
2005). To date, no studies have addressed the
effects of exposure to CAPs in isolation on
vascular function, nor have any previous stud-
ies assessed the effect of these exposures in an
at-risk population of patients with established
coronary heart disease. In the present study,
we included the ultrafine (particles < 0.15 µm
in aerodynamic diameter) fraction of PM. We
aimed to assess the effects of a 2-hr exposure
to fine and ultrafine CAPs on peripheral vas-
cular vasomotor and fibrinolytic function in
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Function in Patients with Coronary Heart Disease
Nicholas L. Mills,1 Simon D. Robinson,1 Paul H. B. Fokkens,2 Daan L. A. C. Leseman,2 Mark R. Miller,1
David Anderson,3 Evelyn J. Freney,4 Mathew R. Heal,4 Robert J. Donovan,4 Anders Blomberg,5
Thomas Sandström,5 William MacNee,3 Nicholas A. Boon,1 Ken Donaldson,3 David E. Newby,1
and Flemming R. Cassee2
1Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; 2National Institute for Public Health and the
Environment (RIVM), Bilthoven, Netherlands; 3ELEGI Colt Laboratory, Centre for Inflammation Research, University of Edinburgh,
Edinburgh, United Kingdom; 4School of Chemistry, University of Edinburgh, Edinburgh, United Kingdom; 5Department of Respiratory
Medicine and Allergy, Umeå University, Umeå, Sweden 
BACKGROUND: Exposure to fine particulate air pollution is associated with increased cardiovascular
morbidity and mortality. We previously demonstrated that exposure to dilute diesel exhaust causes
vascular dysfunction in humans.
OBJECTIVES: We conducted a study to determine whether exposure to ambient particulate matter
causes vascular dysfunction.
METHODS: Twelve male patients with stable coronary heart disease and 12 age-matched volunteers
were exposed to concentrated ambient fine and ultrafine particles (CAPs) or filtered air for 2 hr using
a randomized, double-blind cross-over study design. We measured peripheral vascular vasomotor
and fibrinolytic function, and inflammatory variables—including circulating leukocytes, serum
C-reactive protein, and exhaled breath 8-isoprostane and nitrotyrosine—6–8 hr after both exposures.
RESULTS: Particulate concentrations (mean ± SE) in the exposure chamber (190 ± 37 µg/m3) were
higher than ambient levels (31 ± 8 µg/m3) and levels in filtered air (0.5 ± 0.4 µg/m3; p < 0.001).
Chemical analysis of CAPs identified low levels of elemental carbon. Exhaled breath 8-isoprostane
concentrations increased after exposure to CAPs (16.9 ± 8.5 vs. 4.9 ± 1.2 pg/mL, p < 0.05), but
markers of systemic inflammation were largely unchanged. Although there was a dose-dependent
increase in blood flow and plasma tissue plasminogen activator release (p < 0.001 for all), CAPs
exposure had no effect on vascular function in either group.
CONCLUSIONS: Despite achieving marked increases in particulate matter, exposure to CAPs—low
in combustion-derived particles—did not affect vasomotor or fibrinolytic function in either middle-
aged healthy volunteers or patients with coronary heart disease. These findings contrast with previ-
ous exposures to dilute diesel exhaust and highlight the importance of particle composition in
determining the vascular effects of particulate matter in humans.
KEY WORDS: air pollution, blood flow, endothelium, fibrinolysis, inflammation. Environ Health
Perspect 116:709–715 (2008). doi:10.1289/ehp.11016 available via http://dx.doi.org/ [Online 22
February 2008]
Research
patients with stable coronary heart disease and
in age-matched healthy controls.
Materials and Methods
Subjects. Twelve male patients with stable
coronary heart disease and 12 age-matched,
male, nonsmoking volunteers participated in
these studies, which were performed with the
approval of the local research ethics committee,
in accordance with the Declaration of Helsinki
(World Medical Association 2000), and the
written informed consent of all volunteers. 
Patients with previous myocardial infarc-
tion or stable angina treated by angioplasty
and stenting (> 6 months before enrollment)
were recruited from the outpatient clinic in
the cardiology department at the Royal
Infirmary Edinburgh (Edinburgh, Scotland,
UK). Patients with symptomatic angina pec-
toris (Canadian Cardiovascular Society grade
≥ 2; Campeau et al. 1976) or those unable to
achieve stage 2 of the Bruce protocol (Bruce
1971) were excluded from the study.
Similarly, we excluded any patients with a
history of arrhythmia, diabetes mellitus,
uncontrolled hypertension, renal or hepatic
failure, or unstable coronary disease (acute
coronary syndrome or unstable symptoms
within 3 months). Matched control subjects
were not taking regular medication and had
no clinical evidence of atherosclerotic vascular
disease, diabetes mellitus, hypertension, or
renal or hepatic failure.
In both groups, current smokers and
those with asthma, significant occupational
exposure to air pollution, or an intercurrent
illness were excluded from the study. All sub-
jects had normal lung function as measured
by spirometry, and none of them reported
symptoms of respiratory tract infection dur-
ing the study or in the preceding 6 weeks.
Study design. Subjects attended the clinic
on two occasions at least 2 weeks apart and
received CAPs or filtered air in a randomized,
double-blind cross-over design. Each subject
was exposed for 2 hr in a specially built
whole-body exposure chamber. During each
exposure subjects performed moderate exer-
cise (minute ventilation 25 L/min/m2) on a
bicycle ergometer that was alternated with
rest periods at 15-min intervals.
Based on previous exposure (Mills et al.
2005) and systemic inflammatory (Salvi et al.
1999) studies, we performed vascular assess-
ments 6–8 hr after CAPs or filtered air expo-
sure. All subjects abstained from alcohol for
24 hr and from food and caffeine-containing
drinks for at least 4 hr before each vascular
study. Studies were carried out in a quiet, tem-
perature-controlled room maintained at
22–24°C with subjects supine. All subjects
remained indoors between the exposure and
the vascular assessment to minimize additional
exposure to particulate air pollution.
Concentrated ambient particle exposures
and characterization. We used a Versatile
Aerosol Concentration Enrichment System
(VACES) concentrator (Kim et al. 2001),
within a Mobile Ambient Particle Con-
centrator Exposure Laboratory (MAPCEL) to
deliver exposures to concentrated CAPs and fil-
tered air. The CAPs were derived from an
urban background site outside the Royal
Infirmary Edinburgh (Ordnance Survey Grid
Reference, NT 289 703) approximately
6 miles from the center of Edinburgh. A bus
route passed adjacent to the MAPCEL, and an
arterial city route was located a few hundred
meters away. To maximize differences in expo-
sure and minimize the influence of ambient
pollution, most CAPs exposures were con-
ducted when ambient pollution levels were
high. On the day of the first exposure, the
MAPCEL technicians made a considered judg-
ment as to whether atmospheric conditions
were better suited to conducting a CAPs or fil-
tered air exposure, and subjects were random-
ized accordingly. The study investigators and
staff remained blinded to exposure allocation
throughout the study.
A schematic diagram of the MAPCEL and
VACES used to deliver CAPs and filtered air to
human subjects is given in Figure 1. Incoming
ambient air (500 L/min) is saturated with water
vapor to increase the size of PM2.5 before the air
is passed through five parallel virtual impactors,
each operating at 100 L/min. This increase in
size and therefore mass ensures that particles
have sufficient momentum to pass through the
impactors exiting in the minor flow (5 L/min)
in which the particle concentration is enriched
by a factor of 10- to 20-fold. Of note, particles
> 3 µm are lost by impaction on the walls of the
inlet and saturator and do not pass through this
system. Similarly, particles < 15–20 nm do not
grow in the condensation unit and are lost to
the exhaust in the major flow from the
impactors. The outward minor flow from the
five impactors (25 L/min) is desaturated by sil-
ica gel dryers to restore the particles to their
original size and diluted with filtered air before
delivery into the human exposure chamber
(50 L/min).
We continuously monitored the air in the
exposure chamber for temperature, humidity,
nitrogen oxides [chemiluminescence NO-NO2-
NOx analyzer; Thermo Environmental
Instruments (TEI), Franklin, MA, USA], car-
bon monoxide (gas filter correlation CO ana-
lyzer; TEI) sulfur dioxide (pulsed fluorescence
SO2 analyzer; TEI), and ozone (absorption
ozone analyzers model 8810; Monitor Labs,
San Diego, CA, USA). We determined particle
number using a condensation particle counter
(Model 3022A; Thermo Systems Incorporated,
St. Paul, MN, USA). Particle mass was contin-
uously monitored using a DataRam neph-
elometer (Measuring Instruments for the
Environment Corporation, Bedford, MA,
USA) with the precise mass determined by
gravimetric filter measurements (Teflon
2.0 µm, 4.7 mm; PALL Life Sciences, Ann
Arbor, MI, USA). The concentration of CAPs
was not standardized for all subjects because
exposures were dependent on ambient PM
levels on the day of the study. We aimed to
deliver approximately 200 µg/m3 to allow
comparison with previously published studies
(Mills et al. 2005).
We used an aerosol time-of-flight mass
spectrometer (ATOFMS; TSI) to characterize
single particles sampled during the CAPS
exposures. The operation of the ATOFMS
instrument has been described in detail else-
where (Toner et al. 2006), and detailed results
are presented elsewhere (Freney et al. 2006).
Mills et al.
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Figure 1. A schematic diagram of the VACES used to deliver CAPs and filtered air to human subjects.
Abbreviations: CO, carbon monoxide; CPC, condensation particle counter; NOx, nitrogen oxides; Q, quartz
filter; RH, relative humidity; SMPS, scanning mobility particle sizer; SO2, sulfur dioxide; T, temperature;
T1 and T2, teflon filters. See “Materials and Methods” for details. 
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Vascular studies. All subjects underwent
brachial artery cannulation with a 27-gauge
steel needle under controlled conditions. After
a 30-min baseline saline infusion, acetylcholine
at 5, 10, and 20 µg/min [endothelium-
dependent vasodilator that does not release
tissue plasminogen activator (t-PA); Merck
Biosciences, Läufelfingen, Switzerland],
bradykinin at 100, 300, and 1,000 pmol/min
(endothelium-dependent vasodilator that
releases t-PA; Merck Biosciences), and sodium
nitroprusside at 2, 4, and 8 µg/min (endothe-
lium-independent vasodilator that does not
release t-PA; David Bull Laboratories,
Warwick, UK) were infused for 6 min at each
dose. The three vasodilators were separated by
20-min saline infusions and given in a ran-
domized order. We measured forearm blood
flow in the infused and noninfused arms by
venous occlusion plethysmography using
mercury-in-silastic strain gauges as described
previously (Newby et al. 1999). We monitored
supine heart rate and blood pressure in the
noninfused arm at intervals throughout each
study using a semiautomated, noninvasive
oscillometric sphygmomanometer. For each
subject, venous cannulae (17 gauge) were
inserted into large subcutaneous veins of the
ante-cubital fossae of both arms. Blood
(10 mL) was withdrawn simultaneously from
each arm at baseline and during the infusion of
each dose of bradykinin, and collected into
acidified buffered citrate (Stabilyte tubes;
Biopool International, Ventura, CA, USA) for
t-PA assays, and citrate (BD Vacutainer;
Franklin Lakes, NJ, USA) for plasminogen
activator inhibitor type 1 (PAI-1) assays.
Samples were kept on ice and then centrifuged
at 2,000 × g for 30 min at 4°C. Platelet-free
plasma was decanted and stored at –80°C
before assays. We determined plasma t-PA and
PAI-1 antigen concentrations by ELISA
(enzyme-linked immunosorbant assay kits:
TintElize t-PA, Biopool International; Coaliza
PAI-1, Chromogenix AB, Mölndal, Sweden).
Intraassay coefficients of variation were 7.0%
and 5.5% for t-PA and PAI-1 antigen, with
interassay coefficients of variability of 4.0%
and 7.3%, respectively. We determined hemat-
ocrit by capillary tube centrifugation at base-
line and during infusion of bradykinin
1,000 pmol/min.
Blood samples were taken immediately
before exposure and at 6 and 24 hr after the
exposure and analyzed for total cells, differen-
tial count, and platelets using an autoanalyzer.
We measured serum C-reactive protein
(CRP) concentrations using a highly sensitive
immunonephelometric assay (Behring BN II
nephelometer, Dade-Behring, Marburg,
Germany). Intraassay and interassay coefficients
of variability were 3.0% and 4.6%, respectively.
Exhaled breath condensate. In a pilot study,
exhaled breath condensate (EBC) was collected
using a Jaeger Ecoscreen (VIASYS Healthcare,
Hoechberg, Germany) immediately before
exposure and at 6 and 24 hr after exposures in
eight healthy volunteers. Subjects rinsed their
mouths with water immediately before the col-
lection. We collected EBC during a 10-min
period of normal tidal breathing through the
mouthpiece with a nose clip in place. Samples
were placed on ice immediately after collection
and aliquoted for storage at –80°C within
30 min. We measured 8-isoprostane and
nitrotyrosine in EBC using commercially avail-
able ELISA kits (Quantikine; R&D Systems,
Minneapolis, MN, USA). The intraassay and
interassay coefficients of variation for the assays
were 5% and 6%, respectively.
Data analysis and statistics. Plethysmo-
graphic data were analyzed as described previ-
ously (Newby et al. 1999). Estimated net
release of t-PA antigen was defined as the
product of the infused forearm plasma flow
(based on the mean hematocrit and the
infused forearm blood flow) and the concen-
tration difference between the infused and
noninfused arms (Newby et al. 1997; Oliver
et al. 2005). We based the sample size of
12 subjects in each group on power calcula-
tions derived from previous studies to give
90% power of detection for a 17% difference
in mean t-PA release and a 22% difference in
forearm blood flow at a significance level of
5% (Newby et al. 1997, 1999). Continuous
variables are reported as mean ± SE. Statistical
analyses were performed with GraphPad Prism
(GraphPad Software, San Diego, CA, USA)
using analysis of variance (ANOVA) with
repeated measures, Pearson’s correlation, two-
tailed Student’s t-test, or Fisher’s exact test
where appropriate. The area under the curve
was calculated for the estimated net release of
t-PA during the forearm study period.
Statistical significance was taken at p < 0.05.
Results
All patients had proven coronary heart disease
with a previous myocardial infarction or sta-
ble angina treated by angioplasty and stenting
(> 6 months before enrollment) and were
receiving standard secondary preventive ther-
apy (Table 1). Subjects tolerated the expo-
sures well and did not report any symptoms
during the exposure or in the 24 hr after each
exposure. Patients were well matched for age
and blood pressure but had greater body mass
index than the healthy controls (p < 0.05).
Exposures. Ambient PM concentrations
during the exposure period were variable
(range, 3–174 µg/m3) across the 3-month dura-
tion of the study, with an average ambient con-
centration of 20 ± 4 µg/m3. Although we were
able to enrich the concentration of PM 6- to
8-fold, variation in ambient levels resulted in a
wide range of PM exposures between 50 and
682 µg/m3. Average PM concentrations in the
CAPs exposures (190 ± 37 µg/m3) were greater
than those for ambient levels and filtered air (31
± 8 µg/m3 and 0.5 ± 0.4 µg/m3, respectively;
p < 0.001). We found no significant differences
between concentrations of gaseous copollutants
between the filtered air or CAPs exposures
(Table 2). There were, however, differences in
humidity and temperature in the chamber
CAPs and vascular function
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Table 1. Baseline characteristics of coronary heart disease patients and controls.
Characteristic Controls Patients p-Value
Age (years) 54 ± 2 59 ± 2 0.12
Height (cm) 181 ± 1 176 ± 2 0.03
Weight (kg) 81 ± 3 87 ± 3 0.14
Body mass index (m2/kg) 25 ± 1 28 ± 1 0.02
FEV1 (L) 3.4 ± 0.1 3.0 ± 0.2 0.04
FVC (L) 4.6 ± 0.2 4.2 ± 0.2 0.07
FEV1/FVC 74 ± 1 72 ± 2 0.32
Systolic blood pressure (mmHg) 135 ± 5 138 ± 6 0.69
Diastolic blood pressure (mmHg) 77 ± 3 80 ± 3 0.50
Heart rate (beats per minute) 63 ± 3 54 ± 1 0.006
Previous myocardial infarction 0 7 0.005
Previous PTCA 0 7 0.005
Previous CABG 0 1 0.5
Current smokers 0 0 1.0
Ex-smokers 3 5 0.67
Nonsmokers 9 7 0.67
Hypertension 0 4 0.09
Hypercholesterolemia 0 12 < 0.001
Drugs
Aspirin 0 12 < 0.001
Statins 0 12 < 0.001
Beta blockers 0 11 < 0.001
ACE inhibitors/ARBa 0 7 0.001
Abbreviations: ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass
grafting; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; PTCA, percutaneous transluminal coronary
arteriography. Values shown are mean ± SE or number.
aACE inhibitor therapy was withdrawn 7 days before each vascular study; all other regular medications were continued
throughout the study. 
between the CAPs and filtered air exposures
that occurred as a result of the saturation and
dilution phases of the enrichment process.
Using the ATOFMS, elemental analysis
of ambient PM was acquired during each 2-hr
exposure for a representative 2-week period of
the study. The ATOFMS detected low levels
of carbon (5.3 ± 1.2% of all analysed parti-
cles) and sodium chloride (91.7 ± 6.5%) as
the primary chemical constituents of ambient
aerosol (Figure 2). 
Vascular function. We observed no differ-
ences in resting heart rate, blood pressure, or
baseline forearm blood flow after exposure to
CAPs or filtered air in either cohort (Table 3).
Bradykinin, acetylcholine, and sodium nitro-
prusside caused dose-dependent increases in
forearm blood flow following both air and
CAPs exposure (p < 0.0001); however, this
increase in blood flow was not affected by
exposure to CAPs or filtered air in either
patients or controls (Figure 3). Bradykinin
caused a dose-dependent increase in plasma
t-PA antigen concentrations (p < 0.0001) that
was similarly unaffected by exposure
(Table 4). We found no correlation between
peak forearm blood flow and particle mass or
particle number in the CAPs exposure for any
of the vasodilators infused.
Markers of oxidative stress and inflamma-
tion. EBC levels of 8-isoprostane, produced by
oxidation of tissue phospholipids, increased
6 and 24 hr after CAPs exposure compared
with exposure to filtered air (ANOVA,
p = 0.04; Figure 4), whereas levels of nitrotyro-
sine, an indicator of nitrosative stress, did not
significantly differ between exposures. In all
subjects, we observed a small increase in the
number of circulating platelets (234 ± 8 vs.
225 ± 8 × 109/L; p = 0.007) at 2 hr and mono-
cytes (0.58 ± 0.03 vs. 0.53 ± 0.03 × 109/L;
p = 0.03) at 6 hr after exposure to CAPs com-
pared with exposure to filtered air (Table 5).
There was, however, no clear evidence of a
systemic inflammatory response to CAPs
exposure: Total leukocyte, neutrophil, and
lymphocyte counts or serum CRP concentra-
tions were unaltered by CAPs or air exposure
at any time point.
Discussion
Exposure to concentrated ambient PM in a
typical urban environment for 2 hr did not
affect vascular vasomotor or endogenous fibri-
nolytic function in either middle-aged healthy
volunteers or patients with coronary heart dis-
ease. The ambient PM was generally low in
elemental carbon, indicating that combustion
sources were not a major source of ambient
particulate. However, inhalation of CAPs
caused mild pulmonary oxidative stress, which
did not result in a significant systemic inflam-
matory response. Exposure to particulate air
pollution low in combustion component, at
concentrations 3- to 5-fold higher than the
U.S. Environmental Protection Agency (EPA)
National Ambient Air Quality Standards
(NAAQS; U.S. EPA 2008), is unlikely to cause
adverse vascular effects capable of triggering an
acute coronary event.
These findings contrast with those from
our previous studies in which we reported
impairment of vascular function in both
healthy volunteers and patients with coronary
heart disease after a 1-hr exposure to dilute
diesel exhaust (Mills et al. 2005; Törnqvist
et al. 2007). This apparent discrepancy
requires further discussion, with differences in
particle number, particle composition, and
the presence of gaseous copollutants between
these exposures potentially responsible. 
Ambient particle and diesel exhaust expo-
sures. We were able to increase the concentra-
tion of ambient PM 6- to 8-fold to deliver
exposures between 50 and 682 µg/m3. The
majority of exposures were substantially higher
than the U.S. EPA standard of 35 µg/m3 for
daily PM2.5 (U.S. EPA 2008). Exposure to
190 µg/m3 for 2 hr is roughly comparable to a
1-hr exposure to the 300 µg/m3 of diesel
Mills et al.
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Table 2. Exposure variables.
Variable Air CAPs p-Value
PM (Teflon filter) (µg/m3) — 178 ± 46 < 0.001
PM (quartz filter) (µg/m3) — 162 ± 22 < 0.001
PM (DataRam) (µg/m3) 0.5 ± 0.4 190 ± 37 < 0.001
Ambient PM (DataRam) (µg/m3) 9 ± 1 31 ± 8 0.01
Particle number (1,000 × number/cm3) — 99.4 ± 9.5 < 0.001
Ozone (ppb) 6.0 ± 1.3 5.0 ± 1.2 0.52
Carbon monoxide (ppb) 27 ± 1 24 ± 3 0.40
Sulfur dioxide (ppb) 0.13 ± 0.07 0.13 ± 0.07 1.00
Nitric oxide (ppb) 4.5 ± 0.3 4.6 ±1.0 0.93
Nitrogen dioxide (ppb) 5.9 ± 0.7 5.1 ± 1.0 0.52
NOx (NO + NO2) (ppb) 6.3 ± 0.7 7.2 ± 1.7 0.60
Temperature (°C) 21.1 ± 0.2 20.1 ± 0.2 0.004
Relative humidity (%) 28 ± 2 57 ± 2 < 0.001
Values shown are mean ± SE or number (n = 24). 
Figure 2. ATOFMS analysis of ambient particulate during each 2-hr exposure in a representative 2-week
period. Data are presented as the percentage of particles analyzed containing calcium, elemental carbon,
silicon, vanadium, and sodium chloride or aged NaCl. The ATOFMS detected NaCl as the primary chemical
constituent of ambient aerosol, and only low levels of elemental carbon.
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exhaust particulate delivered in previous stud-
ies. We are confident that these estimates of
exposure are accurate because we determined
the precise mass by gravimetric filter measure-
ments. It is possible that vascular dysfunction
only occurred in subjects exposed to the high-
est concentrations of CAPs and that a signifi-
cant overall effect of exposure to CAPs on
vascular function was masked by those volun-
teers receiving only modest particle exposures.
This seems unlikely, however, given we found
no relationship between particle number or
mass and vasodilatation to any of the endothe-
lial-dependent or endothelial-independent
agonists infused.
Although we delivered a similar mass of PM
in the present study and previous exposures to
diesel exhaust, there were important differences
in particle size and therefore particle number
concentration between the exposures. In dilute
diesel exhaust, the PM consists of pure com-
bustion-derived carbon nanoparticulate. These
particles typically range from 20 to 120 nm,
with a count median diameter of 54 nm (geo-
metric SD = 1.7 nm) (Mills et al. 2007). The
VACES system does not include particles
< 15 nm in the exposure atmosphere, and the
mean particle size in a typical CAPs exposure
was 1.23 ± 0.4 µm in diameter. Therefore, the
total number of suspended particles in dilute
diesel exhaust was 10-fold more than in the
CAPs exposure. Toxicologic studies have deter-
mined that the adverse oxidative and pro-
inflammatory effects of particles are in part
determined by surface area (Duffin et al. 2007;
Oberdorster et al. 2005; Warheit et al. 2007).
It follows that smaller particles exert a greater
effect per unit mass than larger particles of sim-
ilar toxicity. It is therefore possible that the lack
of adverse vascular effects after exposure to
CAPs reflects the much lower number of
nano-sized particles in the present study.
Diesel exhaust is a complex mixture of
gases and particles, and although we hypothe-
size that our previous findings are principally
due to an effect of combustion-derived parti-
cles, it is not possible to definitively exclude a
nonparticulate cause of the adverse vascular
effects. Potentially important copollutants pro-
duced in the combustion of diesel oil include
NOx and CO. One of the advantages of the
VACES system is that it allows us to study the
effects of particulates alone, and the enrich-
ment process does not alter the concentration
of gaseous pollutants. Concentrations of NO2
and CO were low and easily within the recom-
mended NAAQS (U.S. EPA 2008) in our pre-
sent study. In epidemiologic studies, ambient
NO2 or CO have been primarily considered
surrogates for traffic-derived pollution
(Brunekreef and Holgate 2002), but it is possi-
ble that these and other organic gaseous pollu-
tants in diesel exhaust exert a synergistic effect
with the particulates.
As an important source of combustion-
derived particulate, diesel exhaust is strongly
implicated in the observed adverse effects of
air pollution. A variable proportion of urban
PM is attributable to combustion-derived
nanoparticles from traffic, ranging from 20%
at remote monitoring sites (Lanki et al. 2006)
up to 70% in a road tunnel (Geller et al.
2005). In Edinburgh CAPs, only 5% of parti-
cles analyzed contained elemental carbon, and
the principle constituent was pure, mixed, or
reacted sea salts (90%). This is not surprising
given Edinburgh’s maritime climate. Air-mass
source attribution plots for the 5 days before
arrival at the sampling location were calcu-
lated for each of the exposure periods using a
CAPs and vascular function
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Figure 4. EBC levels of 8-isoprostane (A) and nitrotyrosine (B) in healthy volunteers (n = 8) at 6 and 24 hr
after exposure to CAPs or filtered air. (A) EBC levels of 8-isoprostane increased at both time points after
CAPs exposure (ANOVA, p = 0.04, CAPS compared to filtered air). (B) Nitrotyrosine concentrations did not
change significantly (ANOVA, p = 0.21). Values shown are mean ± SE. 
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Table 4. Plasma t-PA antigen concentrations after exposure to filtered air or CAPs.
Air CAPs
Bradykinin (pmol/min) 0 100 300 1,000 0 100 300 1,000
tPA (ng/mL)
Noninfused arm 7.6 ± 0.5 7.4 ± 0.5 7.9 ± 0.5 8.5 ± 0.5 7.2 ± 0.5 7.3 ± 0.6 7.7 ± 0.5 8.6 ± 0.5
Infused arm 7.3 ± 0.5 8.8 ± 0.5 9.7 ± 0.6 14.3 ± 1.2* 7.3 ± 0.6 8.6 ± 0.6 9.5 ± 0.7 14.2 ± 1.1*
Difference –0.4 ± 0.2 1.4 ± 0.4 1.9 ± 0.4 5.8 ± 1.1* 0.1 ± 0.2 1.3 ± 0.4 1.7 ± 0.4 5.7 ± 1.0*
Net t-PA release –1 ± 1 11 ± 3 20 ± 5 90 ± 18* 0 ± 1 12 ± 4 24 ± 6 104 ± 19*
(ng/100 mL tissue/min)
Values shown are mean ± SE (n = 24). 
*p < 0.0001 (ANOVA; dose response). 
Figure 3. Infused and noninfused forearm blood flow in all subjects (n = 24) after CAPs and filtered air expo-
sures during intrabrachial infusion of bradykinin (A), acetylcholine (B), and sodium nitroprusside (C). Values
shown are mean ± SE. For all dose responses in the infused arm, p < 0.0001. p-Values for CAPs versus fil-
tered air are as follows: bradykinin, p = 0.20; acetylcholine, p = 0.17; and sodium nitroprusside, p = 0.14. 
25
20
15
10
5
0
100 300 1,000 5 10 20 2 4 8
Bradykinin (pmoL/min) Acetylcholine (μg/min) Sodium nitroprusside (μg/min)
Fo
re
ar
m
 b
lo
od
 fl
ow
(m
L/
10
0 
m
L 
tis
su
e/
m
in
)
A B CFiltered air
CAPs
Infused
Noninfused
Table 3. Hemodynamic variables 6 hr after exposure in all subjects.
Exposure
Variable Air CAPs p-Value
Heart rate (beats per minute) 58 ± 2 58 ± 1 0.94
Systolic blood pressure (mmHg) 135 ± 4 135 ± 4 0.51
Diastolic blood pressure (mmHg) 78 ± 2 78 ± 2 0.96
Mean arterial pressure (mmHg) 97 ± 2 97 ± 3 0.70
Infused FBF (mL/100 mL tissue/min) 2.6 ± 0.3 2.5 ± 0.2 0.57
Noninfused FBF (mL/100 mL tissue/min) 2.7 ± 0.2 2.3 ± 0.2 0.16
FBF, forearm blood flow. Values shown are mean ± SE (n = 24), two-tailed paired t-test.
U.K. Meterological Office model (Manning
et al. 2003). In all cases, air clearly originated
either predominantly from the Atlantic or the
Arctic, with very little contribution from air
passing over land apart from final arrival over
central Scotland (Freney et al. 2006). The
proportion of airborne PM derived from
remote combustion sources is likely to be low.
It is likely that the absence of any detrimental
vascular effects in the present study, in part,
reflects the composition of Edinburgh CAPs,
which are likely to be of very low toxicity.
Although epidemiologic studies propose that
PM mass is the metric most strongly associ-
ated with adverse events, our studies suggest
that composition strongly affects potency and
is likely to be the main effector of outcome.
Air pollution, oxidative stress, and inflam-
mation. A substantial body of evidence sup-
ports a role for oxidative stress in determining
the toxicity of ambient pollution (Donaldson
et al. 2005a) and in the pro-inflammatory
effects of combustion-derived particles
(Donaldson et al. 2005b; Nemmar et al.
2003). Reactive oxidant species arise not only
from the redox potential of the pollutants
themselves but also from the activation of
alveolar epithelial cells or resident macrophages
and the recruitment and activation of circulat-
ing neutrophils. In the present study, we used
an emerging noninvasive method of assessing
pulmonary oxidative stress through collection
of EBC (Montuschi et al. 1999). In the pre-
liminary studies, we found an increase in EBC
8-isoprostane in normal subjects, suggesting
that inhaled ambient particles exert a pro-
oxidant effect in the airways. This is the first
time, to our knowledge, this technique has
been used to assess the effects of exposure to air
pollutants. If these findings can be replicated
and extended in a larger study, breath conden-
sate measures may become a useful biomarker
of PM exposure.
In panel and population studies, PM
exposure is associated with evidence of an
acute-phase response with increased CRP
(Peters et al. 2001b) and plasma fibrinogen
(Pekkanen et al. 2000; Schwartz 2001),
enhanced plasma viscosity (Peters et al. 1997),
and altered hematologic indices (Seaton et al.
1999). In animal studies, there are similar
reports, with increased fibrinogen in the blood
of PM-exposed hypertensive rats (Cassee et al.
2002, 2005) and normal rats exposed to ultra-
fine carbon particles (Elder et al. 2004). In
recent years CRP has come to prominence as a
biological marker of atherosclerosis, with
serum CRP concentrations, even at very low
levels, predicting the risk of acute myocardial
infarction or stroke in apparently healthy indi-
viduals (Ridker et al. 1997). Serum CRP con-
centrations reflect the burden of vascular
inflammation; however, in the presence of an
intercurrent illness or an exogenous inflamma-
tory stimulus, serum CRP concentrations
increase rapidly as part of the acute-phase
response. We did not find a consistent sys-
temic inflammatory signal after CAPs expo-
sure: there were no changes in the numbers of
circulating neutrophils, lymphocytes, or total
leukocytes, even up to 24 hr. Similarly, we did
not find an increase in serum CRP concentra-
tions, suggesting that a 2-hr exposure to CAPs
may not be sufficient to induce a sustained
systemic inflammatory response.
The number of circulating platelets
increased 2 hr after CAPs exposure, and a simi-
lar transient effect on circulating monocytes
was present at 6 hr. Whether these small
changes are likely to increase cardiovascular
risk is questionable. The cellular mechanisms
of atherosclerosis are complex, but adhesion of
platelets and monocytes to the damaged arter-
ial wall occurs early in response to vascular
injury (Fuster et al. 1992). Activated platelets
deposit at sites of plaque rupture and may pre-
cipitate coronary artery occlusion. Platelet–
monocyte aggregates are increased in cigarette
smokers (Harding et al. 2004) and in patients
with unstable angina (Sarma et al. 2002), sug-
gesting that leukocyte–platelet interactions
may contribute to, or be a marker of, athero-
matous plaque instability. Although we did not
measure markers of platelet or monocyte acti-
vation in our study, Frampton et al. (2006)
recently reported that inhalation of carbon
ultrafine particles alters leukocyte expression of
adhesion molecules in peripheral blood. 
Study limitations. Using a robust random-
ized, double-blind sham-exposure study design,
we have assessed the effect of CAPs on two
complementary aspects of vascular function.
Impaired vasodilation and fibrinolytic func-
tion in the forearm vascular bed have previ-
ously been shown to independently predict
adverse outcomes in patients with coronary
heart disease (Heitzer et al. 2001; Robinson
et al. 2007), and therefore we believe this
model is a reasonable surrogate for cardio-
vascular health. Furthermore, these studies
were conducted in a highly relevant popula-
tion of patients with existing coronary heart
disease who are likely to be susceptible to the
adverse effects of air pollution and for whom
a better understanding of the effects of expo-
sure to particulate air pollution is of clinical
importance. The findings are clear: A 2-hr
exposure to increased concentrations of ambi-
ent PM in an urban setting does not have sig-
nificant effects on systemic vascular function.
Our findings are consistent with the only
previous study of the cardiovascular effects of
CAPs in humans (Brook et al. 2002); in that
study, the authors assessed the effect of a 2-hr
exposure to CAPs using a concentrator tech-
nology that does not enrich ultrafine particles
(Sioutas et al. 1997). Flow-mediated dilation
assessed by ultrasound of the brachial artery
was used to determine conduit vessel function
rather than venous occlusion plethysmogra-
phy that measures peripheral resistance vessel
function. Although CAPs exposure did not
affect endothelium-dependent or indepen-
dent vasodilatation in Brook et al.’s study, it
did induce vasoconstriction of the brachial
artery. It is possible that our CAPs exposures
would have induced similar effects on conduit
arterial tone because this may not be reflected
in changes in basal forearm blood flow meas-
ured by venous occlusion plethysmography.
It is not possible to generalize our findings
or state that exposure to PM is not likely to
exert harmful vascular effects in other urban
settings. This is primarily because the mar-
itime climate and location of the MAPCEL
resulted in an exposure to low levels of com-
bustion component. The concentrator tech-
nology relies on environmental conditions on
the study date to ensure that a relevant expo-
sure can be delivered, and therefore we were
not able to give a prespecified concentration
of ambient particulate. While we delivered
almost 200 µg/m3 CAPS, it is possible that
Mills et al.
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Table 5. Systemic effects of exposure to filtered air or CAPs.
Air CAPs
Preexposure 2 hr 6 hr 24 hr Preexposure 2 hr 6 hr 24 hr ANOVA
Leukocytes (× 109 cells/L) 5.8 ± 0.2 5.8 ± 0.2 6.4 ± 0.2 5.6 ± 0.2 5.8 ± 0.2 6.1 ± 0.2 6.4 ± 0.2 5.5 ± 0.2 0.31
Neutrophils (× 109 cells/L) 3.2 ± 0.1 3.5 ± 0.1 3.9 ± 0.2 3.3 ± 0.1 3.3 ± 0.1 3.7 ± 0.2 3.9 ± 0.2 3.2 ± 0.2 0.58
Lymphocytes (× 109 cells/L) 1.7 ± 0.1 1.5 ± 0.1 1.7 ± 0.1 1.5 ± 0.2 1.6 ± 0.1 1.6 ± 0.1 1.8 ± 0.1 1.5 ± 0.1 0.47
Monocytes (× 109 cells/L) 0.57 ± 0.03 0.50 ± 0.03 0.53 ± 0.03 0.49 ± 0.03 0.55 ± 0.04 0.55 ± 0.04 0.58 ± 0.04* 0.50 ± 0.03 0.02
Platelets (× 109 cells/L) 221 ± 7 225 ± 8 218 ± 7 223 ± 7 224 ± 8 234 ± 8* 217 ± 6 228 ± 8 0.04
CRP (mg/L) 1.2 ± 0.2 — 1.1 ± 0.2 1.3 ± 0.2 1.3 ± 0.2 — 1.2 ± 0.2 1.2 ± 0.2 0.72
PAI-1 antigen (ng/mL) 57 ± 5 33 ± 3 19 ± 2 48 ± 5 63 ± 5 34 ± 3 19 ± 2 51 ± 4 0.30
t-PA antigen (ng/mL) 10.1 ± 0.6 10.6 ± 0.7 7.2 ± 0.5 10.6 ± 0.7 10.2 ± 0.8 10.5 ± 0.7 7.2 ± 0.5 10.9 ± 0.7 0.86
Values shown are mean ± SE (n = 24). Repeated-measure ANOVA CAPs versus filtered air. 
*p < 0.05; Student’s t-test, CAPs versus filtered air (time point). 
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higher concentrations even of low toxicity
CAPs would have had more potent adverse
effects. Further studies in different cities and
city locations are clearly warranted.
Conclusions
Despite achieving substantial increases in
ambient PM concentrations in an urban set-
ting, exposure to ambient particulate air pol-
lution for 2 hr had no effect on vascular
vasomotor or endogenous fibrinolytic func-
tion in either healthy middle-aged volunteers
or patients with established coronary heart
disease. These findings suggest that exposure
to PM that is low in combustion component
is unlikely to exert significant vascular effects
capable of triggering an acute coronary event.
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